Scpharmaceuticals Net Worth
Scpharmaceuticals Net Worth Breakdown | SCPH |
Scpharmaceuticals Net Worth Analysis
Scpharmaceuticals' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Scpharmaceuticals' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Scpharmaceuticals' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Scpharmaceuticals' net worth analysis. One common approach is to calculate Scpharmaceuticals' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Scpharmaceuticals' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Scpharmaceuticals' net worth. This approach calculates the present value of Scpharmaceuticals' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Scpharmaceuticals' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Scpharmaceuticals' net worth. This involves comparing Scpharmaceuticals' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Scpharmaceuticals' net worth relative to its peers.
Enterprise Value |
|
To determine if Scpharmaceuticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Scpharmaceuticals' net worth research are outlined below:
| Scpharmaceuticals had very high historical volatility over the last 90 days | |
| Scpharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 13.59 M. Net Loss for the year was (54.81 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Scpharmaceuticals currently holds about 55.85 M in cash with (59.24 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.04. | |
| Scpharmaceuticals has a poor financial position based on the latest SEC disclosures | |
| Roughly 57.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Investors in scPharmaceuticals have unfortunately lost 23 percent over the last year |
Scpharmaceuticals uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Scpharmaceuticals. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Scpharmaceuticals' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 27th of March 2024 Upcoming Quarterly Report | View | |
| 8th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 27th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Scpharmaceuticals' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Scpharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Scpharmaceuticals backward and forwards among themselves. Scpharmaceuticals' institutional investor refers to the entity that pools money to purchase Scpharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | State Street Corp | 2024-06-30 | 648.3 K | Geode Capital Management, Llc | 2024-06-30 | 581.8 K | Rice Hall James & Associates, Llc | 2024-06-30 | 497.2 K | Stonepine Capital Management Llc | 2024-06-30 | 421.7 K | Walleye Trading Advisors, Llc | 2024-06-30 | 374.4 K | Bank Of Montreal | 2024-06-30 | 351.8 K | Bmo Capital Markets Corp. | 2024-06-30 | 351.8 K | Northern Trust Corp | 2024-06-30 | 247.9 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 221.3 K | Orbimed Advisors, Llc | 2024-06-30 | 5.6 M | Rubric Capital Management Lp | 2024-06-30 | 3.5 M |
Follow Scpharmaceuticals' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 259.15 M.Market Cap |
|
Project Scpharmaceuticals' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.58) | (0.61) | |
| Return On Capital Employed | (0.68) | (0.65) | |
| Return On Assets | (0.58) | (0.61) | |
| Return On Equity | (1.47) | (1.40) |
When accessing Scpharmaceuticals' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Scpharmaceuticals' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Scpharmaceuticals' profitability and make more informed investment decisions.
Evaluate Scpharmaceuticals' management efficiency
Scpharmaceuticals has return on total asset (ROA) of (0.4202) % which means that it has lost $0.4202 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.6689) %, meaning that it created substantial loss on money invested by shareholders. Scpharmaceuticals' management efficiency ratios could be used to measure how well Scpharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.61. The Scpharmaceuticals' current Return On Capital Employed is estimated to increase to -0.65. As of now, Scpharmaceuticals' Non Currrent Assets Other are increasing as compared to previous years. The Scpharmaceuticals' current Other Current Assets is estimated to increase to about 3.8 M, while Total Assets are projected to decrease to under 90.6 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.97 | 0.92 | |
| Tangible Book Value Per Share | 0.97 | 0.92 | |
| Enterprise Value Over EBITDA | (4.29) | (4.50) | |
| Price Book Value Ratio | 6.49 | 6.81 | |
| Enterprise Value Multiple | (4.29) | (4.50) | |
| Price Fair Value | 6.49 | 6.81 | |
| Enterprise Value | 234.9 M | 246.7 M |
The analysis of Scpharmaceuticals' management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze Scpharmaceuticals' future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of Scpharmaceuticals Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.
Enterprise Value Revenue 10.8953 | Revenue 24 M | Quarterly Revenue Growth 3.917 | Revenue Per Share 0.619 | Return On Equity (1.67) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Scpharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Scpharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Scpharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Scpharmaceuticals Corporate Filings
| 28th of August 2024 Other Reports | ViewVerify | |
F3 | 15th of August 2024 An amendment to the original Schedule 13D filing | ViewVerify |
8K | 14th of August 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 13th of August 2024 Other Reports | ViewVerify |
Scpharmaceuticals Earnings per Share Projection vs Actual
Scpharmaceuticals Corporate Management
| John PharmD | Senior Affairs | Profile | |
| Rachael Nokes | Principal Accounting Officer | Profile | |
| Katherine Taudvin | Director Relations | Profile | |
| Michael Hassman | Senior Operations | Profile | |
| Steve Parsons | Senior Commercial | Profile |
Additional Information and Resources on Investing in Scpharmaceuticals Stock
When determining whether Scpharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Scpharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Scpharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Scpharmaceuticals Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Scpharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. For more detail on how to invest in Scpharmaceuticals Stock please use our How to Invest in Scpharmaceuticals guide.You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Scpharmaceuticals. If investors know Scpharmaceuticals will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Scpharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.56) | Revenue Per Share 0.619 | Quarterly Revenue Growth 3.917 | Return On Assets (0.42) | Return On Equity (1.67) |
The market value of Scpharmaceuticals is measured differently than its book value, which is the value of Scpharmaceuticals that is recorded on the company's balance sheet. Investors also form their own opinion of Scpharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Scpharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Scpharmaceuticals' market value can be influenced by many factors that don't directly affect Scpharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Scpharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Scpharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Scpharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.